Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1984 Aug;37(8):852–858. doi: 10.1136/jcp.37.8.852

Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial.

E H Cooper, M A Forbes, R A Crockson, I C MacLennan
PMCID: PMC498880  PMID: 6206095

Abstract

Proximal renal tubular function was studied in 522 consecutive patients entered into the Medical Research Council's fourth myelomatosis trial. Assessment was made at presentation after a 48 h period of hydration but before administration of chemotherapy. The most common abnormalities in the urine other than light chain proteinuria were raised concentrations of the low molecular weight proteins alpha 1-microglobulin and alpha 1-acid glycoprotein. These were usually accompanied by increases in urinary beta-N-acetyl-D-glucosaminidase concentrations. The concentration of these substances in the urine directly correlated with urinary free light chain output. This tubular proteinuria was seen whether or not patients had impaired glomerular function, as assessed by a rise in serum creatinine concentration. Urinary concentrations of retinol binding protein, however, were generally increased only when serum creatinine concentrations were raised. This applied even when there were high concentrations of light chains, alpha 1-microglobulin, alpha 1-acid glycoprotein, and beta-N-acetyl-D-glucosaminidase in the urine. There is therefore a selective tubular proteinuria in myelomatosis which is seen in almost all patients with urinary light chain values greater than 1 u/l. This proteinuria is generally reversible, when light chains no longer appear in the urine. Patients whose serum creatinine was greater than 200 mumol/l, however, had increased urinary output of retinol binding protein in addition to increased excretion of alpha 1-microglobulin, alpha 1-acid glycoprotein, and beta-N-acetyl-D-glucosaminidase. Tubular proteinuria in many of these patients presenting in renal failure persisted even when light chain output was reduced after chemotherapy.

Full text

PDF
852

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults. Br Med J (Clin Res Ed) 1984 May 12;288(6428):1411–1416. doi: 10.1136/bmj.288.6428.1411. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berggård B., Ekström B., Akerström B. alpha 1-Microglobulin. Scand J Clin Lab Invest Suppl. 1980;154:63–71. [PubMed] [Google Scholar]
  3. Bernstein S. P., Humes H. D. Reversible renal insufficiency in multiple myeloma. Arch Intern Med. 1982 Nov;142(12):2083–2086. [PubMed] [Google Scholar]
  4. Boesken W. H. Die tubuläre Proteinurie. Klin Wochenschr. 1975 May 15;53(10):473–479. doi: 10.1007/BF01468633. [DOI] [PubMed] [Google Scholar]
  5. Clyne D. H., Pollak V. E. Renal handling and pathophysiology of Bence Jones proteins. Contrib Nephrol. 1981;24:78–87. doi: 10.1159/000395232. [DOI] [PubMed] [Google Scholar]
  6. Cooper E. H., Stone J. Acute phase reactant proteins in cancer. Adv Cancer Res. 1979;30:1–44. doi: 10.1016/s0065-230x(08)60893-3. [DOI] [PubMed] [Google Scholar]
  7. DeFronzo R. A., Cooke C. R., Wright J. R., Humphrey R. L. Renal function in patients with multiple myeloma. Medicine (Baltimore) 1978 Mar;57(2):151–166. doi: 10.1097/00005792-197803000-00003. [DOI] [PubMed] [Google Scholar]
  8. Engström W., Hyldahl L., Wahrgren P. Urinary excretion of beta 2-microglobulin in myeloma patients. Clin Chim Acta. 1980 Dec 22;108(3):369–374. doi: 10.1016/0009-8981(80)90343-5. [DOI] [PubMed] [Google Scholar]
  9. Finkel P. N., Kronenberg K., Pesce A. J., Pollak V. E., Pirani C. L. Adult Fanconi syndrome, amyloidosis and marked kappa-light chain proteinuria. Nephron. 1973;10(1):1–24. doi: 10.1159/000180174. [DOI] [PubMed] [Google Scholar]
  10. Kjellström T., Evrin P. E., Rahnster B. Dose-response analysis of cadmium-induced tubular proteinuria: a study of urinary beta2-microglobulin excretion among workers in a battery factory. Environ Res. 1977 Apr;13(2):303–317. doi: 10.1016/0013-9351(77)90106-2. [DOI] [PubMed] [Google Scholar]
  11. Kyle R. A. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975 Jan;50(1):29–40. [PubMed] [Google Scholar]
  12. LEABACK D. H., WALKER P. G. Studies on glucosaminidase. 4. The fluorimetric assay of N-acetyl-beta-glucosaminidase. Biochem J. 1961 Jan;78:151–156. doi: 10.1042/bj0780151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Maldonado J. E., Velosa J. A., Kyle R. A., Wagoner R. D., Holley K. E., Salassa R. M. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med. 1975 Mar;58(3):354–364. doi: 10.1016/0002-9343(75)90601-4. [DOI] [PubMed] [Google Scholar]
  15. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  16. Martinez-Maldonado M., Yium J., Suki W. N., Eknoyan G. Renal complications in multiple myeloma: pathophysiology and some aspects of clinical management. J Chronic Dis. 1971 Jul;24(4):221–227. doi: 10.1016/0021-9681(71)90076-2. [DOI] [PubMed] [Google Scholar]
  17. Matthes K. J. Drug-induced proteinuria. Contrib Nephrol. 1981;24:109–114. doi: 10.1159/000395235. [DOI] [PubMed] [Google Scholar]
  18. Mogensen C. E., Sølling Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest. 1977 Oct;37(6):477–486. doi: 10.3109/00365517709101835. [DOI] [PubMed] [Google Scholar]
  19. Price R. G., Dance N., Richards B., Cattell W. R. The excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase following surgery to the kidney. Clin Chim Acta. 1970 Jan;27(1):65–72. doi: 10.1016/0009-8981(70)90375-x. [DOI] [PubMed] [Google Scholar]
  20. Scarpioni L., Ballocchi S., Bergonzi G., Cecchettin M., Dall'Aglio P., Fontana F., Gandi U., Pantano C., Poisetti P. G., Zanazzi M. A. Glomerular and tubular proteinuria in myeloma. Relationship with Bence Jones proteinuria. Contrib Nephrol. 1981;26:89–102. doi: 10.1159/000396106. [DOI] [PubMed] [Google Scholar]
  21. Smithline N., Kassirer J. P., Cohen J. J. Light-chain nephropathy. Renal tubular dysfunction associated with light-chain proteinuria. N Engl J Med. 1976 Jan 8;294(2):71–74. doi: 10.1056/NEJM197601082940202. [DOI] [PubMed] [Google Scholar]
  22. Solomon A. Bence Jones proteins: malignant or benign? N Engl J Med. 1982 Mar 11;306(10):605–607. doi: 10.1056/NEJM198203113061010. [DOI] [PubMed] [Google Scholar]
  23. Virella G., Pires M. T., Coelho I. M. Analytical characterization of the urinary proteins from sixty patients with monoclonal gammopathies. Clin Chim Acta. 1974 Jan 19;50(1):63–75. doi: 10.1016/0009-8981(74)90078-3. [DOI] [PubMed] [Google Scholar]
  24. Weise M., Prüfer D., Jaques G., Keller M., Mondorf A. W. Beta 2-microglobulin and other proteins as parameter for tubular function. Contrib Nephrol. 1981;24:88–98. doi: 10.1159/000395233. [DOI] [PubMed] [Google Scholar]
  25. Yu H., Cooper E. H., Settle J. A., Meadows T. Urinary protein profiles after burn injury. Burns Incl Therm Inj. 1983 May;9(5):339–349. doi: 10.1016/0305-4179(83)90081-5. [DOI] [PubMed] [Google Scholar]
  26. Yu H., Yanagisawa Y., Forbes M. A., Cooper E. H., Crockson R. A., MacLennan I. C. Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol. 1983 Mar;36(3):253–259. doi: 10.1136/jcp.36.3.253. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES